Parametric Portfolio Associates’s Allogene Therapeutics ALLO Stock Holding History

Parametric Portfolio Associates’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$617K	Sell	67,750 -43,094	-39%	-$449K	﹤0.01%	2997
2021 Q4	$1.65M	Buy	110,844 +68,338	+161%	+$1.21M	﹤0.01%	2562
2021 Q3	$1.09M	Sell	42,506 -8,127	-16%	-$193K	﹤0.01%	2765
2021 Q2	$1.32M	Buy	50,633 +15,626	+45%	+$446K	﹤0.01%	2651
2021 Q1	$1.24M	Buy	35,007 +21,838	+166%	+$737K	﹤0.01%	3063
2020 Q4	$332K	Buy	13,169 +3,069	+30%	+$100K	﹤0.01%	3552
2020 Q3	$381K	Sell	10,100 -18,337	-64%	-$691K	﹤0.01%	3385
2020 Q2	$1.22M	Buy	+28,437	New	+$1.03M	﹤0.01%	2809
2020 Q1	–	Sell	-7,963	Closed	-$207K	–	3918
2019 Q4	$207K	Buy	+7,963	New	+$219K	﹤0.01%	3732

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Parametric Portfolio Associates's ALLO Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Allogene Therapeutics (ALLO) stake by 39% in Q1 2022, selling an estimated $449K and leaving 67,750 shares worth $617K. The position accounts for ﹤0.01% of the portfolio, ranked #2997.

Parametric Portfolio Associates first reported a position in ALLO in Q4 2019 and has held it in 9 quarters since. The position peaked at $1.65M in Q4 2021. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

Parametric Portfolio Associates held 67,750 shares of Allogene Therapeutics worth $617K as of Q1 2022.
Parametric Portfolio Associates sold 43,094 Allogene Therapeutics shares in Q1 2022, an estimated $449K.
Allogene Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2997 holding.
Parametric Portfolio Associates first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 9 quarters since.
Parametric Portfolio Associates's Allogene Therapeutics position peaked at $1.65M in Q4 2021.
180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.